搜尋
Roivant Sciences Ltd
ROIV添加自選
33.625USD
+1.415+4.39%
交易中 （美東）報價延遲15分鐘
23.86B總市值
虧損本益比TTM
關於 Roivant Sciences Ltd 公司
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd簡介
公司代碼ROIV
公司名稱Roivant Sciences Ltd
上市日期Dec 03, 2020
CEOVenker (Eric)
員工數量750
證券類型Ordinary Share
年結日Dec 03
公司地址7Th Floor, 50 Broadway
城市LONDON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United Kingdom
郵編SW1H 0DB
電話4412955950
網址http://roivant.com/
公司代碼ROIV
上市日期Dec 03, 2020
CEOVenker (Eric)
Roivant Sciences Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.58M
-1.18%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.75%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
-2.36%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
113.36K
+13.79%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
101.64K
+0.79%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.00K
+0.40%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
76.72K
-24.71%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
68.00
-60575.00%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-100.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.58M
-1.18%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.75%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
-2.36%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
113.36K
+13.79%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
101.64K
+0.79%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.00K
+0.40%
常見問題
Roivant Sciences Ltd的前五大股東是誰？
Roivant Sciences Ltd的前五大股東如下：Dr. Frank M. Torti, M.D.
有多少機構持有Roivant Sciences Ltd(ROIV)的股份？
截至2026Q1，共有781家機構持有Roivant Sciences Ltd的股份，合計持有的股份價值約為565.52M，占公司總股份的79.01% 。與2025Q4相比，機構持股有所增加，增幅為-23023750.00。
